These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 9269701

  • 1. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?
    Buter H, Hemmelder MH, van Paassen P, Navis G, de Zeeuw D, de Jong PE.
    Nephrol Dial Transplant; 1997; 12 Suppl 2():53-6. PubMed ID: 9269701
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 4. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 5. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2005 Oct; 39(6):511-7. PubMed ID: 16303729
    [Abstract] [Full Text] [Related]

  • 6. Dual renin-angiotensin system blockade: in patients with single functioning kidney and proteinuria.
    Robles NR, Ruiz Jiménez B, Hernández Gallego R, Ruiz-Calero R, Sánchez Casado E, Cubero JJ.
    Eur J Intern Med; 2009 Mar; 20(2):186-9. PubMed ID: 19327610
    [Abstract] [Full Text] [Related]

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 8. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.
    van der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, Mayer G, de Zeeuw D.
    Kidney Int Suppl; 1997 Dec; 63():S23-6. PubMed ID: 9407415
    [Abstract] [Full Text] [Related]

  • 10. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 11. Long-term antiproteinuric effect of dual renin-angiotensin system blockade.
    Robles NR, Fernandez Carbonero E, Romero B, Sánchez Casado E, Cubero JJ.
    Cardiovasc Ther; 2009 Jan; 27(2):101-7. PubMed ID: 19426247
    [Abstract] [Full Text] [Related]

  • 12. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
    Minutolo R, Gabbai FB, Borrelli S, Scigliano R, Trucillo P, Baldanza D, Laurino S, Mascia S, Conte G, De Nicola L.
    Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
    [Abstract] [Full Text] [Related]

  • 13. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H, Kanno Y, Nakamoto H, Okada H, Sugahara S.
    Clin Exp Hypertens; 2005 Dec; 27(2-3):129-38. PubMed ID: 15835375
    [Abstract] [Full Text] [Related]

  • 14. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 Dec; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 15. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 16. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E.
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [Abstract] [Full Text] [Related]

  • 17. [Clinical effects of trandolapril in chronic glomerulonephritis patients with renal insufficiency].
    Yoshida A, Takeda A, Fukuda M, Toda S, Morozumi K.
    Nihon Jinzo Gakkai Shi; 2000 May; 42(4):333-7. PubMed ID: 10897592
    [Abstract] [Full Text] [Related]

  • 18. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.
    Boero R, Rollino C, Massara C, Vagelli G, Gonella M, Berto IM, Bajardi P, Perosa P, Malcangi U, Giorgi MP, Ghezzi PM, Borzumati M, Baroni AM, Cogno C, Triolo G, Angelini D, Antonelli A, Quarello F.
    J Nephrol; 2001 May; 14(1):15-8. PubMed ID: 11281338
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH, NIGRAM Consortium.
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [Abstract] [Full Text] [Related]

  • 20. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.